PhALLCON, the first randomized study comparing tyrosine kinase inhibitors in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), evaluated ponatinib vs imatinib in combination with reduced-intensity chemotherapy. Results were presented by Jabbour et al during the February ASCO Plenary Series session (Abstract 398868).
